Rx only · Tablet · Oral

Clorazepate Dipotassium

7 ACTIVE SUPPLIERS — US

openFDA · updated weekly

US22 NDCs
7 active makers

UKComing
soon

CAComing
soon

AUComing
soon

EUComing
soon

ATC—

RxCUI (US)—

US makers7 labelers

Packages42

DEA / ScheduleCIV

US acquisition costNADAC · per unit

Average across 29 priced NDCs. A benchmark of pharmacy acquisition cost — not a retail quote.

$0.799

Latest avg · Jul 22, 2026

-23%

Since Dec 17, 2025

Active US suppliers

50%

Top-2 supplier share*

Medicaid dispensing volumeSDUD · per quarter

Prescriptions dispensed under Medicaid (fee-for-service + managed care), summed nationally. The closest free proxy to sales volume — Medicaid only, not all-payer.

6.8K

Rx · 2026 Q1

473K

Units dispensed

-24%

Rx vs. year ago

Quarters · since 2025 Q1

Who makes it7 active · 0 exited

US labelers as registered with FDA. Repackagers relabel another company's product; share* is of listed packages, not sales.

Labeler	Type	Packages	Status
ANI Pharmaceuticals, Inc.	unknown	11	SUPPLYING
Aurolife Pharma, LLC	unknown	10	SUPPLYING
SUN PHARMACEUTICAL INDUSTRIES, INC.	unknown	9	SUPPLYING
NorthStar Rx LLC	unknown	5	SUPPLYING
Apotex Corp.	unknown	3	SUPPLYING
Coupler LLC	unknown	3	SUPPLYING
PD-Rx Pharmaceuticals, Inc.	unknown	1	SUPPLYING

Regulatory & supply eventsFDA · US

Shortages, recalls, and registration changes attached to this drug concept.

Apr 24, 2024
RECALLRecall (Class II): Clorazepate Dipotassium Tablets, USP, 3.75 mg, a) 100 tablets per bottle, NDC 13107-282-01 b) 500 tablets per bottle, N…
Discoloration: Dotted and yellow spots on tablets — Recalling firm: Aurobindo Pharma USA Inc. — Nationwide in the USA
Apr 24, 2024
RECALLRecall (Class II): Clorazepate Dipotassium Tablets, USP, 7.5 mg, a) 100 tablets per bottle, NDC 13107-283-01, b) 500 tablets per bottle, N…
Discoloration: Dotted and yellow spots on tablets — Recalling firm: Aurobindo Pharma USA Inc. — Nationwide in the USA